C75 MedChemExpress (MCE)

Product Name	3-CARBOXY-4-OCTYL-2-METHYLENEBUTYROLACTONE
Synonyms	C75 FAS inhibitor C75(C-75 3-CARBOXY-4-OCTYL-2-METHYLENEBUTYROLACTONE TRANS-4-CARBOXY-5-OCTYL-3-METHYLENEBUTYROLACTONE 3-Furancarboxylic acid, tetrahydro-4-methylene-2-octyl-5-oxo- C75(4-Methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylicacid) Synonyms C75 FAS inhibitor C75(C-75 3-CARBOXY-4-OCTYL-2-METHYLENEBUTYROLACTONE TRANS-4-CARBOXY-5-OCTYL-3-METHYLENEBUTYROLACTONE 3-Furancarboxylic acid, tetrahydro-4-methylene-2-octyl-5-oxo- C75(4-Methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylicacid) TRANS-TETRAHYDRO-3-METHYLENE-2-OXO-5-N-OCTYL-4-FURANCARBOXYLIC ACID
CAS	218137-86-1
EINECS
Chemical Formula	C14H22O4
Molecular Weight	254.32
inchi
Package	10 mM * 1 mL;2 mg;5 mg;10 mg;25 mg;50 mg
Price	Email to quote
Descriptions	C75 C75 MedChemExpress (MCE) HY-12364 218137-86-1 99.91% Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Room temperature in continental US Descriptions C75 C75 MedChemExpress (MCE) HY-12364 218137-86-1 99.91% Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Room temperature in continental US may vary elsewhere. C75 is a synthetic fatty-acid synthase (FASN) inhibitor inhibits prostate cancer cells PC3 with an IC50 of 35 μM. C75 is a potent CPT1A activator. C75 inhibits PC3 cell growht with an IC50 of 35 μM at 24 h. C75 (10-50 μM) also reduces the growth of LNCaP spheroids in a concentration-dependent manner with an IC50 of 50 μM[1]. (-)-C75 inhibits FAS activity and has a cytotoxic effect on tumor cell lines, without affecting food consumption. (+)-C75 inhibits CPT1 and its administration produces anorexia, suggesting that central inhibition of CPT1 is essential for the anorectic effect of C75. The differential activity of C75 enantiomers may lead to the development of potential new specific drugs for cancer and obesity[2]. C75 blocks fasting-induced c-Fos expression in the arcuate nucleus (Arc), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) 10–24 h after i.p. injection. Intraperitoneal administration of C75 at 30 mg/kg body weight inhibits food intake of mice by ≥95% within 2 h after i.p. injection[3]. C75-treated DIO mice has a 50% greater weight loss, and a 32.9% increased production of energy because of fatty acid oxidation. C75 treatment of rodent adipocytes and hepatocytes and human breast cancer cells increases fatty acid oxidation and ATP levels by increasing CPT-1 activity, even in the presence of elevated concentrations of malonyl-CoA[4]. Mice: C75 is administered either by i.p. (i.p. 30 mg/kg of body weight) or i.c.v. (10 μg in 3 μL of RPMI medium 1640) injection. One, 11.5, and 24 h after i.p. injection, cumulative food intake is measured, mice are killed, brains are sectioned, and slices are subjected to immunohistochemical staining for c-Fos. All i.p. injections are given 1 h before the start of the dark cycle. For i.c.v. injection, mice are anesthetized with metofane and given 3 μl of RPMI medium 1640 (control) or C75 in RPMI medium 1640 into the lateral ventricle with a calibrated 10-μl Hamilton syringe[3]. Cells are seeded in 96-well plates and incubated for 2 days to allow exponential phase growth. Cells are then ished twice with PBS and treated with C75. After 24 or 48 h incubation, MTT is added to a final concentration of 0.5 mg/ml and cultures are incubated for 2 h. Cells are then solubilized with DMSO before measuring absorbance at 570 nm. Cell growth is also measured, using MTT assay, every 24 h up to 96 h[1]. IC50: 35 μM (PC3 cell)[1] Cellular Effect Cell Line Type Value Description References \| \| \| \| \| \| \| \| \| \| [1]. Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. [Content Brief] [2]. Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug (-)-C75 has antitumor activity. Chirality. 2013 May 25(5):281-7. [Content Brief] [3]. Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13 100(10):5628-33. [Content Brief] [4]. Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9 99(14):9498-502. [Content Brief] [5]. Yan Xue, et al. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation. 2021 Mar 1 105(3):550-560. [Content Brief]
Supplier Website	http://www.medchemexpress.com/C75.html
Last Update	2025-10-14 16:03:33

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-10-14 16:03:33

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-10-14 16:03:33

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-10-14 16:03:33

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-10-14 16:03:33

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-10-14 16:03:33

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-10-14 16:03:33

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-10-14 16:03:33

Thalidomide-PEG4-NH2

Category: Signaling Pathways
CAS: 2387510-82-7
Last Update: 2025-10-14 16:03:33


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	http://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact